NewAmsterdam Pharma Ownership

NAMS Stock

20.80 0.04 0.19%

NewAmsterdam Pharma maintains a total of 92.39 Million outstanding shares. The majority of NewAmsterdam Pharma outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in NewAmsterdam Pharma to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in NewAmsterdam Pharma. Please pay attention to any change in the institutional holdings of NewAmsterdam Pharma as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Some institutional investors establish a significant position in stocks such as NewAmsterdam Pharma in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of NewAmsterdam Pharma, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

Dividend Paid And Capex Coverage Ratio is likely to gain to -5,590 in 2024. Common Stock Shares Outstanding is likely to gain to about 86.3 M in 2024, whereas Net Loss is likely to drop (27 M) in 2024.

Market Cap Enterprise Value

Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NewAmsterdam Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

For more information on how to buy NewAmsterdam Stock please use our How to Invest in NewAmsterdam Pharma guide.

NewAmsterdam Stock Ownership Analysis

About 84.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 2.21. NewAmsterdam Pharma had not issued any dividends in recent years. The entity had 1:1 split on the 23rd of November 2022. To find out more about NewAmsterdam Pharma contact FACC Facp at 31 35 206 2971 or learn more at https://www.newamsterdampharma.com.

Besides selling stocks to institutional investors, NewAmsterdam Pharma also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different NewAmsterdam Pharma's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align NewAmsterdam Pharma's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.

NewAmsterdam Pharma Quarterly Liabilities And Stockholders Equity

439.19 Million

Less than 1% of NewAmsterdam Pharma are currently held by insiders. Unlike NewAmsterdam Pharma's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against NewAmsterdam Pharma's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of NewAmsterdam Pharma's insider trades

NewAmsterdam Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as NewAmsterdam Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading NewAmsterdam Pharma backward and forwards among themselves. NewAmsterdam Pharma's institutional investor refers to the entity that pools money to purchase NewAmsterdam Pharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.

		Shares
Polar Capital Holdings Plc	2024-06-30	1 M
Deerfield Management Co	2024-09-30	901.8 K
Gmt Capital Corp	2024-06-30	891.8 K
Avidity Partners Management Lp	2024-09-30	889.7 K
Artal Group S A	2024-06-30	800 K
Pictet Asset Manangement Sa	2024-06-30	683.7 K
Citadel Advisors Llc	2024-09-30	522.5 K
Woodline Partners Lp	2024-06-30	483.4 K
Affinity Asset Advisors, Llc	2024-09-30	472.4 K
Fcpm Iii Services Bv	2024-09-30	11.8 M
Bain Capital Life Sciences Investors, Llc	2024-09-30	10.5 M

Note, although NewAmsterdam Pharma's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

NewAmsterdam Pharma Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific NewAmsterdam Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on NewAmsterdam Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases NewAmsterdam Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

		Davidson Michael H. over a month ago Disposition of 15000 shares by Davidson Michael H. of NewAmsterdam Pharma at 11.5 subject to Rule 16b-3
		Louise Kooij over two months ago Acquisition by Louise Kooij of 45000 shares of NewAmsterdam Pharma subject to Rule 16b-3
		Davidson Michael H. over three months ago Acquisition by Davidson Michael H. of 5000 shares of NewAmsterdam Pharma at 16.27 subject to Rule 16b-3
		Mckenna Mark C. over three months ago Acquisition by Mckenna Mark C. of 72500 shares of NewAmsterdam Pharma at 18.81 subject to Rule 16b-3
		Mckenna Mark C. over three months ago Acquisition by Mckenna Mark C. of 72500 shares of NewAmsterdam Pharma at 18.81 subject to Rule 16b-3
		Davidson Michael H. over three months ago Acquisition by Davidson Michael H. of 5000 shares of NewAmsterdam Pharma at 17.2617 subject to Rule 16b-3
		Davidson Michael H. over six months ago Discretionary transaction by Davidson Michael H. of tradable shares of NewAmsterdam Pharma subject to Rule 16b-3
		Jones William A Jr over six months ago Disposition of 130000 shares by Jones William A Jr of NewAmsterdam Pharma at 11.17 subject to Rule 16b-3
		Kastelein Johannes Jacob Pieter over six months ago Disposition of 190476 shares by Kastelein Johannes Jacob Pieter of NewAmsterdam Pharma at 21.5 subject to Rule 16b-3
		Lange Louis G over six months ago Purchase by Lange Louis G of 5000 shares of NewAmsterdam Pharma
		Gallagher Carol Giltner over six months ago Exercise or conversion by Gallagher Carol Giltner of 30000 shares of NewAmsterdam Pharma subject to Rule 16b-3
		Davidson Michael H over six months ago NewAmsterdam Pharma exotic insider transaction detected

NewAmsterdam Pharma Corporate Filings

8K	20th of November 2024 Report filed with the SEC to announce major events that shareholders should know about	View Verify
F4	19th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities	View Verify
F3	15th of November 2024 An amendment to the original Schedule 13D filing	View Verify
13A	14th of November 2024 An amended filing to the original Schedule 13G	View Verify

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for NewAmsterdam Stock Analysis

When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC